康恩貝(600572.SH)擬5000萬元以增資方式取得喜鵲醫藥5.6995%的股權
格隆匯12月17日丨康恩貝(600572.SH)公佈，公司長期以來以現代中藥和植物藥為核心和基礎性業務。為發揮各自優勢，共同謀求在現代中藥和植物藥創新領域的可持續發展，公司擬出資人民幣5000萬元以增資方式取得喜鵲醫藥5.6995%的股權，其中73.33萬元計入註冊資本，4926.67萬元計入資本公積。
此次公司與廣東粵財中小企業股權投資基金合夥企業(有限合夥)、珠海橫琴依星伴月投資合夥企業(有限合夥)、廣州科技金融創新投資控股有限公司擬共同對喜鵲醫藥進行增資投資，喜鵲醫藥此次增資總金額為人民幣1億元，其中146.67萬元計入註冊資本，9853.33萬元計入資本公積，增資完成後喜鵲醫藥的註冊資本將由1140萬元增加至1286.67萬元。
喜鵲醫藥是一家臨牀階段的創新藥物研究與開發公司，基於對國家實現中藥現代化和全球創新藥物發展趨勢的深刻理解，喜鵲醫藥創建了獨具特色的藥物設計理念體系和藥物研發平台，對傳統中藥中的活性天然產物單體或目前臨牀正在使用的小分子化合物進行結構修飾或改造，以期大幅增加活性和功能。
根據國內醫藥行業有關政策變化和產業發展的未來趨勢，公司將進一步以拓展中藥大健康產業及國際化為未來戰略重點。喜鵲醫藥是一家臨牀階段的創新藥物研究與開發公司，搭建了獨具特色的藥物設計理念體系和藥物研發平台，專注於開發具有自主知識產權的創新藥物。公司此次投資參股喜鵲醫藥從而成為喜鵲醫藥的股東並取得相應的權利，作為股東身份有利於公司與喜鵲醫藥在現代植物藥、中藥創新項目研發等業務層面開展進一步合作，利用喜鵲醫藥的創新研發優勢，通過MAH形式或產品權力轉移的形式不斷完善和豐富公司的產品線。同時，基於國家推動實現中藥現代化、促進中醫藥傳承與開放創新發展的市場機遇，公司與喜鵲醫藥可發揮各自優勢，共同謀求在現代中藥和植物藥創新領域的可持續發展，符合公司的發展戰略需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
